AI
Tuesday, May 11, 2010 1:48:40 PM
Uracyst Revenue Estimates
I'm new to the board, but wanted to offer my own bar napkin math estimate for Uracyst based on the Cowen Healthcare Conference presentation on March 8th, 2010. I've basically taken the assumptions provided in that presentation and validated it to make sure it made sense to me.
Overall, the market share and total revenues for Stellar can be quite amazing. This will take considerable time with FDA approval and developing the right sales channels, but we should start to see signficant revenue increases already as the recent European licenses start generating sales. The kicker will obviously be when China and the US approve Uracyst. I have no idea on the China timeline, but Watson expects FDA approval by late 2012. Here are the numbers:
I'm new to the board, but wanted to offer my own bar napkin math estimate for Uracyst based on the Cowen Healthcare Conference presentation on March 8th, 2010. I've basically taken the assumptions provided in that presentation and validated it to make sure it made sense to me.
Overall, the market share and total revenues for Stellar can be quite amazing. This will take considerable time with FDA approval and developing the right sales channels, but we should start to see signficant revenue increases already as the recent European licenses start generating sales. The kicker will obviously be when China and the US approve Uracyst. I have no idea on the China timeline, but Watson expects FDA approval by late 2012. Here are the numbers:
Discover What Traders Are Watching
Explore small cap ideas before they hit the headlines.
